195 related articles for article (PubMed ID: 32780726)
1. PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma.
Sharma G; Ojha R; Noguera-Ortega E; Rebecca VW; Attanasio J; Liu S; Piao S; Lee JJ; Nicastri MC; Harper SL; Ronghe A; Jain V; Winkler JD; Speicher DW; Mastio J; Gimotty PA; Xu X; Wherry EJ; Gabrilovich DI; Amaravadi RK
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32780726
[TBL] [Abstract][Full Text] [Related]
2. PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer.
Rebecca VW; Nicastri MC; Fennelly C; Chude CI; Barber-Rotenberg JS; Ronghe A; McAfee Q; McLaughlin NP; Zhang G; Goldman AR; Ojha R; Piao S; Noguera-Ortega E; Martorella A; Alicea GM; Lee JJ; Schuchter LM; Xu X; Herlyn M; Marmorstein R; Gimotty PA; Speicher DW; Winkler JD; Amaravadi RK
Cancer Discov; 2019 Feb; 9(2):220-229. PubMed ID: 30442709
[TBL] [Abstract][Full Text] [Related]
3. Identification of palmitoyl protein thioesterase 1 in human THP1 monocytes and macrophages and characterization of unique biochemical activities for this enzyme.
Wang R; Borazjani A; Matthews AT; Mangum LC; Edelmann MJ; Ross MK
Biochemistry; 2013 Oct; 52(43):7559-74. PubMed ID: 24083319
[TBL] [Abstract][Full Text] [Related]
4. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization.
Liu N; Zhang J; Yin M; Liu H; Zhang X; Li J; Yan B; Guo Y; Zhou J; Tao J; Hu S; Chen X; Peng C
Mol Ther; 2021 Jul; 29(7):2321-2334. PubMed ID: 33744468
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.
Krueger J; Santinon F; Kazanova A; Issa ME; Larrivee B; Kremer R; Milhalcioiu C; Rudd CE
PLoS One; 2021; 16(6):e0251731. PubMed ID: 34181666
[TBL] [Abstract][Full Text] [Related]
7. A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.
Rebecca VW; Nicastri MC; McLaughlin N; Fennelly C; McAfee Q; Ronghe A; Nofal M; Lim CY; Witze E; Chude CI; Zhang G; Alicea GM; Piao S; Murugan S; Ojha R; Levi SM; Wei Z; Barber-Rotenberg JS; Murphy ME; Mills GB; Lu Y; Rabinowitz J; Marmorstein R; Liu Q; Liu S; Xu X; Herlyn M; Zoncu R; Brady DC; Speicher DW; Winkler JD; Amaravadi RK
Cancer Discov; 2017 Nov; 7(11):1266-1283. PubMed ID: 28899863
[TBL] [Abstract][Full Text] [Related]
8. Binding of hydroxychloroquine and chloroquine dimers to palmitoyl-protein thioesterase 1 (PPT1) and its glycosylated forms: a computational approach.
Vergoten G; Bailly C
J Biomol Struct Dyn; 2022 Nov; 40(18):8197-8205. PubMed ID: 33876698
[TBL] [Abstract][Full Text] [Related]
9. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.
Li X; Zhu S; Yin P; Zhang S; Xu J; Zhang Q; Shi S; Zhang T
Drug Deliv; 2021 Dec; 28(1):1849-1860. PubMed ID: 34515617
[TBL] [Abstract][Full Text] [Related]
11. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
Wei Z; Zhang X; Yong T; Bie N; Zhan G; Li X; Liang Q; Li J; Yu J; Huang G; Yan Y; Zhang Z; Zhang B; Gan L; Huang B; Yang X
Nat Commun; 2021 Jan; 12(1):440. PubMed ID: 33469052
[TBL] [Abstract][Full Text] [Related]
12. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
13. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
15. Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8
Bestion E; Rachid M; Tijeras-Raballand A; Roth G; Decaens T; Ansaldi C; Mezouar S; Raymond E; Halfon P
Target Oncol; 2024 Jan; 19(1):95-106. PubMed ID: 38133710
[TBL] [Abstract][Full Text] [Related]
16. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
18. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
19. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
20. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
